BioSpace News Archive

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced a single-site analysis of data from an ongoing Phase 2a clinical trial of intratumoral NanoPac® suspension showed improved resection rates in locally advanced pancreatic cancer.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the first public release of data generated by the CosMx™ Spatial Molecular Imager.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United States government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted Emergency Use Authorization or approval by the U.S. Food and Drug Administration, for approximately $1 billion.

Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.

Progenity, Inc., an innovative biotechnology company, announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021.

Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

NGM Biopharmaceuticals, Inc. today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences: Stifel 2021 Virtual Healthcare Conference Monday, November 15, 2021

Evaxion Biotech A/S announced today the third quarter 2021 financial results and provided an operational update.

LAVA Therapeutics N.V. today announced the expansion of its management team with the appointments of Jessica Truscello as vice president of clinical operations, Sumeet Ambarkhane, M.D. as executive medical director and Wouter van Hunnik as vice president of human resources.

Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021 Cullinan MICA and Cullinan Florentine programs to advance into clinical trials by year end 2021